Literature DB >> 25122205

Increased risk of osteoporosis in patients with myasthenia gravis: a population-based cohort study.

Jiann-Horng Yeh1, Hsuan-Ju Chen1, Yen-Kung Chen1, Hou-Chang Chiu1, Chia-Hung Kao2.   

Abstract

OBJECTIVE: To determine the risk of osteoporosis in patients with myasthenia gravis (MG) in a large cohort representing 99% of the population of Taiwan.
METHODS: Data from the Taiwan National Health Insurance Research Database were used to conduct retrospective cohort analyses. The study cohort consisted of 2,073 patients with MG who were 3-fold frequency-matched by age and sex and assigned the same index year as a comparison cohort without MG. Cox proportional hazard regression analysis was conducted to estimate the risk of osteoporosis.
RESULTS: The MG cohort had a 1.96-fold increased risk of developing osteoporosis compared with the comparison cohort (hazard ratio [HR] = 1.96, 95% confidence interval [CI] = 1.57-2.44). Patients with MG older than 30 years developed an increased risk of osteoporosis, with the highest risk in the age group from 30 to 44 years, compared with the control cohort. Corticosteroid-naïve patients with MG had a 1.52-fold increased risk of developing osteoporosis (HR = 1.52, 95% CI = 1.11-2.08), and the corticosteroid-treated cohort had a 2.37-fold increased risk of developing osteoporosis (HR = 2.37, 95% CI = 1.82-3.07).
CONCLUSION: This population-based retrospective cohort study provides evidence that MG is associated with a high risk of osteoporosis regardless of corticosteroid use.
© 2014 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25122205     DOI: 10.1212/WNL.0000000000000804

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

1.  Negative impact of high cumulative glucocorticoid dose on bone metabolism of patients with myasthenia gravis.

Authors:  Nayara Felicidade Tomaz Braz; Natalia Pessoa Rocha; Érica Leandro Marciano Vieira; Rodrigo Santiago Gomez; Izabela Guimarães Barbosa; Olívio Brito Malheiro; Adriana Maria Kakehasi; Antonio Lucio Teixeira
Journal:  Neurol Sci       Date:  2017-05-09       Impact factor: 3.307

2.  Association between bone mineral density, muscle strength, and vitamin D status in patients with myasthenia gravis: a cross-sectional study.

Authors:  Y Guan; F Lv; Y Meng; D Ma; X Xu; Y Song; O Wang; Y Jiang; W Xia; X Xing; J Zhang; M Li
Journal:  Osteoporos Int       Date:  2017-04-24       Impact factor: 4.507

3.  Association between Glucocorticoid-Induced Osteoporosis and Myasthenia Gravis: A Cross-Sectional Study.

Authors:  Shingo Konno; Shigeaki Suzuki; Masayuki Masuda; Yuriko Nagane; Emiko Tsuda; Hiroyuki Murai; Tomihiro Imai; Toshiki Fujioka; Norihiro Suzuki; Kimiaki Utsugisawa
Journal:  PLoS One       Date:  2015-05-12       Impact factor: 3.240

4.  Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravis.

Authors:  Yuze Cao; Xiaoyan Lu; Jianjian Wang; Huixue Zhang; Zhaojun Liu; Si Xu; Tianfeng Wang; Shangwei Ning; Bo Xiao; Lihua Wang
Journal:  Int J Mol Med       Date:  2017-01-11       Impact factor: 4.101

Review 5.  A Practical Approach to Managing Patients With Myasthenia Gravis-Opinions and a Review of the Literature.

Authors:  Maria Elena Farrugia; John A Goodfellow
Journal:  Front Neurol       Date:  2020-07-07       Impact factor: 4.003

6.  Risk of osteoporosis in patients with chronic inflammatory neuropathy- a population-based cohort study.

Authors:  Seung Woo Kim; Eun Hwa Kim; Jinae Lee; Young-Chul Choi; Seung Min Kim; Ha Young Shin
Journal:  Sci Rep       Date:  2019-06-24       Impact factor: 4.379

7.  Identification of the regulatory role of lncRNA HCG18 in myasthenia gravis by integrated bioinformatics and experimental analyses.

Authors:  Shuang Li; Xu Wang; Tianfeng Wang; Huixue Zhang; Xiaoyu Lu; Li Liu; Lifang Li; Chunrui Bo; Xiaotong Kong; Si Xu; Shangwei Ning; Jianjian Wang; Lihua Wang
Journal:  J Transl Med       Date:  2021-11-18       Impact factor: 5.531

Review 8.  Update on ocular myasthenia gravis in Taiwan.

Authors:  Chao-Wen Lin; Ta-Ching Chen; Jieh-Ren Jou; Lin-Chung Woung
Journal:  Taiwan J Ophthalmol       Date:  2018 Apr-Jun

9.  Bone metabolism is a key factor for clinical outcome of tibial plateau fractures.

Authors:  Matthias Krause; Lena Alm; Markus Berninger; Christoph Domnick; Kai Fehske; Karl-Heinz Frosch; Elmar Herbst; Alexander Korthaus; Michael Raschke; Reinhard Hoffmann
Journal:  Eur J Trauma Emerg Surg       Date:  2020-11-05       Impact factor: 3.693

10.  The use of oral glucocorticoids and the risk of major osteoporotic fracture in patients with myasthenia gravis.

Authors:  Zohreh Safipour; Rogier van der Zanden; Joop van den Bergh; Paddy Janssen; Peter Vestergaard; Frank de Vries; Johanna H M Driessen
Journal:  Osteoporos Int       Date:  2021-10-03       Impact factor: 4.507

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.